Annovis Bio Advances Alzheimer’s Treatment with FDA Approval for Phase 3 Trials
MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has announced a successful outcome from its recent End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA). The FDA has given …
Annovis Bio Advances Alzheimer’s Treatment with FDA Approval for Phase 3 Trials Read More